Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT04937153 2025-07-16

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Phase 1 Completed

18 enrolled

Other solid neoplasm

Solid Tumor

NCT04082572 2025-05-13

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Phase 2 Completed

35 enrolled 10 charts

Other solid neoplasm

Locally Advanced Malignant Solid Neoplasm

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

58 enrolled

Other solid neoplasmThoracic

Solid Tumor

NCT04105335 2025-03-06

TIMEPOINT

Phase 1 Completed

50 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT05176509 2025-01-06

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

Phase 1 Completed

5 enrolled

Other solid neoplasm

Solid Tumor

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT05508100 2024-05-24

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Phase 1 Completed

38 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05277402 2024-02-26

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

6 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT03274661 2023-10-19

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Phase 2 Completed

52 enrolled 12 charts

Other solid neoplasm

Solid Tumor, Adult

NCT03834948 2023-08-22

AO-176 in Multiple Solid Tumor Malignancies

Phase 1/2 Completed

57 enrolled

Other solid neoplasm

Solid Tumor

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

172 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03172819 2022-09-28

Special Combination of OBP-301 and Pembrolizumab

Phase 1 Completed

22 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02132754 2021-01-28

MK-4166-001

Phase 1 Completed

116 enrolled 61 charts

Other solid neoplasm

Solid Tumor

NCT02987166 2020-12-16

UVA-AM-001

Phase 1 Completed

21 enrolled

Other solid neoplasm

Solid Tumor

NCT02843204 2020-05-28

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Phase 1/2 Completed

110 enrolled

Other solid neoplasm

Malignant Solid Tumour

NCT02179918 2019-02-08

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Phase 1 Completed

23 enrolled 27 charts

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

PEMBIB

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

EVICTION-2

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

MK-3475-A17

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

TIMEPOINT

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

AO-176 in Multiple Solid Tumor Malignancies

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Special Combination of OBP-301 and Pembrolizumab

MK-4166-001

UVA-AM-001

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)